What ICD‑10‑CM code should be assigned to a prostate MRI showing a 7 × 4 mm T2‑decreased signal focus in the right posterior medial mid‑peripheral zone suspicious for neoplastic disease and severe heterogeneous enlargement of the transition zone extending into the bladder base (suggestive of benign prostatic hyperplasia)?

ICD-10-CM Coding for Prostate MRI Findings

For this clinical scenario with a PI-RADS suspicious lesion and concurrent BPH, assign code N40.1 (Benign prostatic hyperplasia with lower urinary tract symptoms) for the documented BPH, and code R93.81 (Abnormal findings on diagnostic imaging of other parts of musculoskeletal system) or R93.89 (Abnormal findings on diagnostic imaging of other specified body structures) for the suspicious MRI finding pending tissue diagnosis.

Coding Algorithm for This Scenario

Primary Consideration: Diagnostic Certainty

The MRI describes findings that are "suspicious for" neoplastic disease but explicitly states "clinical follow-up is recommended" rather than confirming malignancy. In ICD-10-CM coding, you cannot assign a definitive cancer code (C61, Malignant neoplasm of prostate) without histopathologic confirmation.

Step-by-Step Coding Approach:

1. Code the Confirmed Diagnosis (BPH):

• The report documents "severe heterogeneous enlargement of the transition zone...suggesting BPH"
• Use N40.1 (Benign prostatic hyperplasia with lower urinary tract symptoms) if the patient has documented LUTS
• Use N40.0 (Benign prostatic hyperplasia without lower urinary tract symptoms) if no LUTS are documented
• The AUA guideline 1 emphasizes proper documentation of BPH with associated symptoms for treatment planning

2. Code the Suspicious Finding:

• For the 7 × 4 mm decreased T2 signal focus suspicious for neoplasm, use:
  • R93.81 or R93.89 (Abnormal findings on diagnostic imaging)
  • Alternatively, R97.20 (Elevated prostate specific antigen [PSA]) if elevated PSA prompted the MRI
  • Do NOT use C61 until biopsy confirmation

3. Consider PI-RADS Category Documentation:

• While the question asks about PI-RADS category, this is a radiologic scoring system (1-5) used for clinical decision-making, not an ICD-10 code 2, 3
• A decreased T2 signal focus in the peripheral zone with restricted diffusion typically corresponds to PI-RADS 4 or 5 depending on size and DWI characteristics 4, 5
• Document the PI-RADS score in the clinical note, but it doesn't translate directly to ICD-10

Critical Coding Pitfalls to Avoid

Never assign C61 (Malignant neoplasm of prostate) based solely on imaging:

• Even highly suspicious MRI findings (PI-RADS 5) require histologic confirmation
• Premature cancer coding can affect insurance coverage, treatment authorization, and patient anxiety
• The EAU guidelines 6 emphasize that MRI-targeted biopsy should follow suspicious findings for definitive diagnosis

Don't overlook the BPH component:

• The severe BPH extending into the bladder base is a significant clinical finding requiring its own code
• This may impact treatment planning if the suspicious lesion proves malignant, as the BPH component affects surgical approach

Document the clinical context:

• Use additional codes for relevant clinical factors:
  • R97.20 if PSA is elevated
  • Z12.5 (Encounter for screening for malignant neoplasm of prostate) if this was a screening MRI
  • Personal or family history codes (Z80.42, Z85.46) if applicable

Post-Biopsy Coding Updates

Once biopsy results are available:

• If malignant: Replace R93.81/R93.89 with C61 and add appropriate ISUP grade group documentation
• If benign: Consider codes for prostatitis (N41.x) or other benign findings based on histology 4
• The EAU guidelines 6 note that each biopsy site should be reported with location, Gleason score, and ISUP grade group, which will guide final ICD-10 coding